Swiss National Bank Increases Stake in Immunome, Inc. $IMNM

Key Points

• The Swiss National Bank increased its stake in Immunome, Inc. by 67.5%, acquiring a total of 128,000 shares valued at approximately $861,000.
• Other institutional investors, including Deutsche Bank AG and Primecap Management Co., also significantly boosted their holdings in Immunome during the first quarter, reflecting growing institutional interest.
• Immunome's stock has gained 2.4% recently, with a current market cap of $884.33 million, despite reporting a negative EPS of ($0.50) in its latest earnings results.

Swiss National Bank raised its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 67.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,000 shares of the company's stock after buying an additional 51,600 shares during the quarter. Swiss National Bank owned about 0.15% of Immunome worth $861,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of IMNM. BNP Paribas Financial Markets purchased a new position in Immunome in the fourth quarter worth approximately $70,000. Tower Research Capital LLC TRC boosted its holdings in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Aquatic Capital Management LLC acquired a new stake in Immunome in the 4th quarter valued at about $95,000. ANTIPODES PARTNERS Ltd acquired a new stake in Immunome in the first quarter valued at approximately $95,000. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Immunome by 140.8% during the 1st quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock worth $115,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

Insiders Place Their Bets

In related news, Director Jean Jacques Bienaime acquired 5,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was bought at an average cost of $9.38 per share, with a total value of $46,900.00. Following the transaction, the director owned 36,415 shares of the company's stock, valued at $341,572.70. The trade was a 15.92% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.69% of the company's stock.

Immunome Stock Performance

Immunome stock traded down $0.39 during midday trading on Monday, hitting $9.51. 684,063 shares of the company's stock were exchanged, compared to its average volume of 648,978. The stock has a market cap of $827.75 million, a price-to-earnings ratio of -3.09 and a beta of 1.92. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.73. The firm's 50 day simple moving average is $9.79 and its 200 day simple moving average is $8.84.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The business had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. On average, equities research analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IMNM. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. cut their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Evercore ISI assumed coverage on shares of Immunome in a research report on Friday, August 22nd. They issued an "outperform" rating and a $18.00 price target for the company. Wedbush restated an "outperform" rating and issued a $21.00 price objective on shares of Immunome in a research note on Thursday, August 7th. Finally, Guggenheim reiterated a "buy" rating and set a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat, Immunome presently has an average rating of "Buy" and a consensus target price of $22.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.